Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Steyr – page 28

449 clinical trials in Steyr, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steyr at a glance
449
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

449 trials in Steyr

Open in trial search

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen - Cilag International

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Not recruiting

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Study on the Safety of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Astrazeneca AB

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Steyr

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative research focusing on multiple myeloma treatment approaches, including maintenance therapy post stem-cell transplantation and comparing different administration methods for targeted therapies. Studies also investigate new treatments for Hodgkin Lymphoma with emphasis on reducing toxicity while maintaining efficacy.

  • Multiple Myeloma Treatments
  • Hodgkin Lymphoma Therapy
  • Stem Cell Transplantation

Advanced clinical research evaluating novel drug combinations and administration routes to improve patient outcomes.

02 Breast Cancer Research

Comprehensive studies examining treatments for ER-positive, HER2-negative breast cancer, including both early-stage and advanced disease. Research focuses on novel therapeutic agents and extended treatment strategies to prevent recurrence.

  • Early Breast Cancer Treatment
  • Advanced Breast Cancer Therapy
  • Endocrine Therapy Innovation

Trials aim to improve current treatment standards and evaluate new therapeutic options for breast cancer patients.

03 Pain Management Studies

Extensive research into chronic pain conditions, including diabetic polyneuropathy, post-operative neuropathy, and chronic back pain. Studies evaluate new treatment approaches for various types of neuropathic and musculoskeletal pain.

  • Neuropathic Pain Treatment
  • Chronic Back Pain Management
  • Post-operative Pain Control

Investigations focus on developing effective add-on treatments for chronic pain conditions to improve patient quality of life.

04 Pancreatic Cancer Research

Advanced studies in metastatic pancreatic ductal adenocarcinoma, evaluating novel combination therapies to improve survival rates. Research focuses on comparing standard treatments with new therapeutic approaches.

  • Metastatic Disease Treatment
  • Combination Therapy Assessment
  • Survival Rate Improvement

Clinical trials aim to enhance treatment outcomes for patients with advanced pancreatic cancer.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.